What is Atomwise?
Founded in 2012 and headquartered in California, Atomwise Inc. operates at the intersection of artificial intelligence and drug discovery. The company utilizes its proprietary AI platform to accelerate the identification and design of novel drug candidates, aiming to significantly reduce the time and cost associated with bringing new therapies to market. Atomwise's technology is designed to analyze vast biological and chemical datasets, enabling researchers to explore a wider range of potential therapeutic compounds than traditional methods allow. This innovative approach positions Atomwise as a key player in the evolving landscape of pharmaceutical R&D, seeking to address unmet medical needs through advanced computational methods.
How much funding has Atomwise raised?
Atomwise has raised a total of $221.6M across 7 funding rounds:
Unspecified
$225K
Other Financing Round
$120K
Angel/Seed
$6M
Series A
$45M
Series B
$123M
Grant
$2.3M
Series C
$45M
Unspecified (2013): $225K with participation from Grand Challenges Canada
Other Financing Round (2015): $120K led by David E. Weekly and Y Combinator
Angel/Seed (2015): $6M supported by Draper Fisher Jurvetson, Data Collective, Khosla Ventures, OS Fund, and AME Cloud Ventures
Series A (2018): $45M featuring B Capital Group, Monsanto Growth Ventures, Tencent, Baidu Ventures, Y Combinator, Khosla Ventures, and Data Collective
Series B (2020): $123M backed by BV, Tencent, Sanabil Investments, Y Combinator, DCVC, B Capital Group, Dolby Family Ventures, and AME Cloud Ventures
Grant (2020): $2.3M with participation from Bill & Melinda Gates Foundation
Series C (2024): $45M led by Khosla Ventures and B Capital Group
Key Investors in Atomwise
Khosla Ventures
Khosla Ventures is a venture capital firm that provides venture assistance and strategic advice to entrepreneurs working on breakthrough technologies, with a broad focus including AI, fintech, health, and sustainable energy.
B Capital Group
B Capital is a venture capital firm that focuses on empowering entrepreneurs by investing in early and late-stage companies within the Technology, Healthcare, and Climate sectors, aiming to support founders throughout the company-building lifecycle.
Y Combinator
Y Combinator is a startup accelerator that provides seed funding for businesses and connects them with investors, fostering the growth of early-stage companies.
What's next for Atomwise?
With the recent infusion of major strategic investment, Atomwise is poised to further enhance its AI capabilities and expand its drug discovery pipeline. The company's trajectory, marked by consistent capital raises from prominent investors, suggests a strong focus on scaling its operations and advancing its therapeutic programs through preclinical and clinical development. This backing will likely fuel further research into novel therapeutic areas and strengthen strategic partnerships within the pharmaceutical industry, reinforcing Atomwise's commitment to revolutionizing drug discovery through cutting-edge artificial intelligence.
See full Atomwise company page
